β-cell dysfunction and insulin resistance in type 2 diabetes: Role of metabolic and genetic abnormalities

American Journal of Medicine

Volumn 113, Issue 6 SUPPL., 2002, Pages 3-11

  LeRoith, Derek ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIAZOXIDE; FATTY ACID; GLUCOSE; METFORMIN; RESISTIN; SULFONYLUREA; TOLBUTAMIDE; TUMOR NECROSIS FACTOR ALPHA;

CALORIC INTAKE; CELL FUNCTION; CONFERENCE PAPER; DISEASE COURSE; EXERCISE; GENETICS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 0037191135     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(02)01276-7     Document Type: Conference Paper

References (48)

1. Gerich J.E. The genetic basis of type 2 diabetes mellitus impaired insulin secretion versus impaired insulin sensitivity . Endocr Rev. 19:1998;491-503.
2. Lebovitz H.E. Pathogenesis of type 2 diabetes. Drug Benefit Trends. 12:(suppl A):2000;8-16.
3. Lebovitz H.E. Type 2 diabetes an overview . Clin Chem. 45:1999;1339-1345.
4. Riddle M.C. Tactics for type II diabetes. Endocrinol Metab Clin North Am. 26:1997;659-677.
5. Groop L.C., Ferrannini E. Insulin action and substrate competition. Ferrannini E., Baillière's Clinical Endocrinology and Metabolism. 1993;1007-1032 Baillière Tindall, London.
6. Groop L.C., Widén E., Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus errors of metabolism or of methods? Diabetologia. 36:1993;1326-1331.
7. Boden G. Fatty acids and insulin resistance. Diabetes Care. 19:1996;394-395.
8. Bergenstal R.M., Kendal D.M., Franz M.J., et al. Management of type 2 diabetes a systemic approach to meeting standards of care. II. Oral agents, insulin and management of complications. Degroot L.J., Jameson J.L., Endocrinology. 4th ed. 2001;WB Saunders, Philadelphia, PA. chap 58.
9. Kahn S.E., Prigeon R.L., McCulloch D.K., et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects evidence for a hyperbolic function . Diabetes. 42:1993;1663-1672.
10. Kahn S.E. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 108:(6A):2000;2S-8S.
11. Knowler W.C., Pettitt D.J., Saad M.F., Bennett P.H. Diabetes mellitus in the Pima Indians incidence, risk factors and pathogenesis . Diabetes Metab Rev. 6:1990;1-27.
12. Weyer C., Bogardus C., Mott D.M., Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 104:1999;787-794.
13. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
14. UK Prospective Diabetes Study Group . U.K. prospective diabetes study 16 overview of 6 years' therapy of type II diabetes: a progressive disease . Diabetes. 44:1995;1249-1258.
15. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man . Diabetologia. 28:1985;412-419.
16. Holman R.R. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 40:(suppl):1998;S21-S25.
17. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:1998;854-865.
18. Berkovitz K., Peters R., Kjos S.L., et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes. 45:1996;1572-1579.
19. Porte D. Jr, Kahn S.E. The key role of islet dysfunction in type II diabetes mellitus. Clin Invest Med. 18:1995;247-254.
20. Porte D. Jr. β-Cells in type II diabetes mellitus. Diabetes. 40:1991;166-180.
21. Henquin J.-C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 49:2000;1751-1760.
22. Aguilar-Bryan L., Bryan J., Nakazaki M. Of mice and men K(ATP) channels and insulin secretion . Recent Prog Horm Res. 56:2001;47-68.
23. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med. 6:2000;907-933.
24. Riddle M.C. Evening insulin strategy. Diabetes Care. 13:1990;676-686.
25. Maedler K., Spinas G.A., Lehmann R., et al. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 50:2001;1683-1690.
26. Kruszynska Y.T., Olefsky J.M. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med. 44:1996;413-428.
27. Watson R.T., Pessin J.E. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res. 56:2001;175-193.
28. Shintani M., Nishimura H., Yonemitsu S., et al. Troglitazone not only increases GLUT4 but also induces its translocation in rat adipocytes. Diabetes. 50:2001;2296-2300.
29. McClain D.A. Hexosamines as mediators of nutrient sensing and regulation in diabetes. J Diabetes Complications. 16:2002;72-80.
30. Kaneto H., Xu G., Song K.-H., et al. Activation of the hexosamine pathway leads to deterioration of pancreatic β-cell function through the induction of oxidative stress. J Biol Chem. 276:2002;31099-31104.
31. Skyler J.S. Insulin therapy in type 2 diabetes mellitus. DeFronzo R.A., Current Therapy of Diabetes Mellitus. 1998;108-116 Mosby-Year Book, St. Louis, MO.
32. Prentki M., Corkey B.E. Are the β-cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes. 45:1996;273-283.
33. Aguilar-Bryan L., Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev. 20:1999;101-135.
34. Kosaka K., Kuzuya T., Akanuma Y., Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia. 18:1980;23-28.
35. Garvey W.T., Olefsky J.M., Griffin J., et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 34:1985;222-234.
36. Randle P.J., Garland P.B., Newsholme E.A., Hales C.N. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci. 131:1965;324-333.
37. Boden G. Free fatty acids - the link between obesity and insulin resistance. Endocr Pract. 7:2001;44-51.
38. Brun T., Assimacopoulos-Jeannet F., Corkey B.E., Prentki M. Long-chain fatty acids inhibit acetyl-CoA carboxylase gene expression in the pancreatic β-cell line INS-1. Diabetes. 46:1977;393-400.
39. Ginsburg HN. Dyslipidemia and diabetes mellitus: pathophysiology and treatment [National Diabetes Education Initiative Web site]. http://www.ndei.org/content/patient/clinical_commandments/dyslipidemia.asp. Accessed July 25, 2001.
40. Pan D.A., Lillioja S., Kriketos M.R., et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 46:1997;983-988.
41. Kelley D.E., Goodpaster B.H. Skeletal muscle triglyceride. Diabetes Care. 24:2001;933-941.
42. Poitout V., Robertson R.P. Minireview secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity . Endocrinology. 143:2002;339-342.
43. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes close association with insulin resistance and hyperinsulinemia . J Clin Endocrinol Metab. 86:2001;1930-1935.
44. Chu N.-F., Spiegelman D., Hotamisligil G.S., et al. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis. 157:2001;495-503.
45. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312.
46. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with lipoatrophy and obesity. Nat Med. 7:2001;941-946.
47. Berg A.H., Combs T.P., Du X., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 7:2001;947-953.
48. Skurk T., Lee Y.-M., Röhrig K., Hauner H. Effect of angiotensin peptides on PAI-1 expression and production in human adipocytes. Horm Metab Res. 33:2001;196-200.